Literature DB >> 2982154

Ha-ras proteins exhibit GTPase activity: point mutations that activate Ha-ras gene products result in decreased GTPase activity.

V Manne, E Bekesi, H F Kung.   

Abstract

Several ras genes have been expressed at high levels in Escherichia coli and the resultant ras proteins were shown to be functional with respect to their well-known specific, high-affinity, GDP/GTP binding. We were able to detect a weak GTPase activity associated with the purified proteins. The normal cellular ras protein (p21N) exhibits approximately equal to 10 times higher GTPase activity than the "activated" proteins. Even though the turnover rate of the reaction is very low (0.02 mol of GTP hydrolyzed per mol of p21N protein per minute), the reaction appears to be catalytic; one molecule of p21N hydrolyzes more than one molecule of GTP. The GTPase and the GDP binding activities both have been recovered from a Mr 23,000 protein eluted following NaDodSO4/polyacrylamide gel electrophoresis, suggesting that these two activities are associated with the same protein. Mg2+ ions and dithiothreitol are required for GTPase activity and the optimal pH is between 7 and 8. Guanidine X HCl, which is required for solubilizing bacterially expressed ras protein, is strongly inhibitory to GTPase activity at concentrations higher than 0.5 M.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982154      PMCID: PMC397041          DOI: 10.1073/pnas.82.2.376

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

1.  Transcripts from the cellular homologs of retroviral oncogenes: distribution among chicken tissues.

Authors:  T J Gonda; D K Sheiness; J M Bishop
Journal:  Mol Cell Biol       Date:  1982-06       Impact factor: 4.272

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Guanine nucleotide binding activity of the src gene product of rat-derived murine sarcoma viruses.

Authors:  E M Scolnick; T Y Shih; J Maryak; R Ellis; E Chang; D Lowy
Journal:  Ann N Y Acad Sci       Date:  1980       Impact factor: 5.691

4.  Altered regulation of the guanosine 5'-triphosphate activity in a kirromycin-resistant elongation factor Tu.

Authors:  O Fasano; A Parmeggiani
Journal:  Biochemistry       Date:  1981-03-03       Impact factor: 3.162

5.  Guanosine nucleotide binding by highly purified Ha-ras-encoded p21 protein produced in Escherichia coli.

Authors:  V Manne; S Yamazaki; H F Kung
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

6.  Expression of normal and transforming H-ras genes in Escherichia coli and purification of their encoded p21 proteins.

Authors:  J C Lacal; E Santos; V Notario; M Barbacid; S Yamazaki; H Kung; C Seamans; S McAndrew; R Crowl
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

7.  Guanine nucleotide-binding and autophosphorylating activities associated with the p21src protein of Harvey murine sarcoma virus.

Authors:  T Y Shih; A G Papageorge; P E Stokes; M O Weeks; E M Scolnick
Journal:  Nature       Date:  1980-10-23       Impact factor: 49.962

8.  [Determination of orthophosphate in the presence of phosphate compounds with an affinity for acids and molybdate].

Authors:  B E WAHLER; A WOLLENBERGER
Journal:  Biochem Z       Date:  1958

9.  Kirromycin, an inhibitor of protein biosynthesis that acts on elongation factor Tu.

Authors:  H Wolf; G Chinali; A Parmeggiani
Journal:  Proc Natl Acad Sci U S A       Date:  1974-12       Impact factor: 11.205

10.  ras-Related gene sequences identified and isolated from Saccharomyces cerevisiae.

Authors:  D DeFeo-Jones; E M Scolnick; R Koller; R Dhar
Journal:  Nature       Date:  1983 Dec 15-21       Impact factor: 49.962

View more
  59 in total

Review 1.  MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer.

Authors:  Sriganesh B Sharma; John Michael Ruppert
Journal:  Drug Dev Res       Date:  2015-08-18       Impact factor: 4.360

2.  Characterization of phosphoinositide-specific phospholipase C from human platelets.

Authors:  V Manne; H F Kung
Journal:  Biochem J       Date:  1987-05-01       Impact factor: 3.857

3.  The H-ras oncogene product p21 and prognosis in human breast cancer.

Authors:  D M Watson; R A Elton; W J Jack; J M Dixon; U Chetty; W R Miller
Journal:  Breast Cancer Res Treat       Date:  1991 Jan-Feb       Impact factor: 4.872

4.  rasH mutants deficient in GTP binding.

Authors:  C J Der; B T Pan; G M Cooper
Journal:  Mol Cell Biol       Date:  1986-09       Impact factor: 4.272

5.  Proteolytic processing of avian sarcoma and leukosis viruses pol-endo recombinant proteins reveals another pol gene domain.

Authors:  F Alexander; J Leis; D A Soltis; R M Crowl; W Danho; M S Poonian; Y C Pan; A M Skalka
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

6.  A transforming ras gene can provide an essential function ordinarily supplied by an endogenous ras gene.

Authors:  A G Papageorge; B M Willumsen; M Johnsen; H F Kung; D W Stacey; W C Vass; D R Lowy
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

7.  Monoclonal antibody Y13-259 recognizes an epitope of the p21 ras molecule not directly involved in the GTP-binding activity of the protein.

Authors:  J C Lacal; S A Aaronson
Journal:  Mol Cell Biol       Date:  1986-04       Impact factor: 4.272

8.  ras p21 deletion mutants and monoclonal antibodies as tools for localization of regions relevant to p21 function.

Authors:  J C Lacal; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

Review 9.  The biochemistry of ras p21.

Authors:  R J Grand; D Owen
Journal:  Biochem J       Date:  1991-11-01       Impact factor: 3.857

10.  Molecular analysis of ras oncogenes in CIN III and in stage I and II invasive squamous cell carcinoma of the uterine cervix.

Authors:  J J O'Leary; R J Landers; I Silva; V Uhlmann; M Crowley; I Healy; K Luttich
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.